#GI25 highlights #CommunityOnc:

1. #SCIENCE: Adv Eso SCC

2. #ESOPEC publication (Eso/GEJ/Ga)

3. Chemo in resectable Panc Ca

4. #StarterNET: GEP-NET

5. #CM8HW: dMMR/MSI-H mCRC

6. #BREAKWATER: BRAFV600E mCRC

7. ctDNA: #BESPOKE + SWOG80702

#OncSky #gism @ascocancer.bsky.social

1/8

🔥NRG GI-007🔥

LA-Esophagus Carcinoma
🔍 dCRT (50.4 Gy/28 fx carbo/taxol) + endoscopically injected oncolytic virus OBP-301

✅💯 cCR rate❗️
✅Comparatively favorable AE profile

👏🏽👏🏽 Brilliant work and looking forward to future study!!

#GI25 @ascocancer.bsky.social

🚨Pooled CAO/ARO/AIO-12 and OPRA Rectal trials🚨

Study suggests that selective WW compared with planned surgery offers:
✅ Comparable OS and DFS!!

🔥 Supports WW as a highly appropriate, and potentially preferable, option for patients with cCR after TNT‼️

#GI25 #CRC @ascocancer.bsky.social

🔥🔥🔥BREAKWATER🔥🔥🔥

BRAF V600E mut #CRC

SOC (FOLFOX) +/- encorafenib + cetuximab

EC + FOLFOX shows:

✅⬆️ORR
✅Strong suggestion of ⬆️OS

🚨EC + FOLFOX is a new SOC‼️

Pub available: idp.nature.com/authorize?re...

#GI25 @ascocancer.bsky.social

🚨🚨CheckMate 8HW🚨🚨

🔥NEW SOC🔥

dMMR/MSI-H mCRC

Ph3 RCT 🔍 Nivo vs Ipi + Nivo

Ipi + Nivo offers:

✅⬆️ Early and sustained PFS
✅favorable safety profile

Pub available: www.thelancet.com/journals/lan...

#GI25 #crc @ascocancer.bsky.social

🚨SCIENCE Ph3 RCT🚨

🔥Check this one out!🔥
cT2-4N0-3, T1N2-3 Eso SCC

1️⃣neo Carbo + nab Paclitaxel + Sintilimab

2️⃣nCRT (41.4/23) w/ Carbo-taxol + Sintilimab

3️⃣nCRT

✅⬆️⬆️pCR CRT vs chemo (only 13% with chemo)
✅Sintilimab + CRT ⬆️ pCR (47%➡️60%) without added AEs

#GI25 @ascopost.bsky.social